The cGAS/STING/IFN-1 Response in Squamous Head and Neck Cancer Cells after Genotoxic Challenges and Abrogation of the ATR-Chk1 and Fanconi Anemia Axis.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
04 Oct 2023
Historique:
received: 11 09 2023
revised: 28 09 2023
accepted: 29 09 2023
medline: 23 10 2023
pubmed: 14 10 2023
entrez: 14 10 2023
Statut: epublish

Résumé

Locally advanced head and neck squamous cell carcinomas (HNSCC) are often refractory to platinum-based radiochemotherapy and new immuno-oncological strategies. To stimulate immunogenic antitumor responses in HNSCC patients, we investigated the cGAS/STING/IFN-1 signaling pathway after genotoxic treatments and concomitant abrogation of the DNA damage response (DDR). For this purpose, FaDu and UM-SCC1 cells were exposed to X-rays or cisplatin and treated with an ATR or Chk1 inhibitor, or by Fanconi anemia gene A knockout (FANCA ko). We assessed clonogenic survival, cell cycle regulation, micronuclei, free cytosolic double-stranded DNA, and the protein expression and activity of the cGAS/STING/IFN-1 pathway and related players. Cell survival, regulation of G2/M arrest, and formation of rupture-prone cGAS-positive micronuclei after genotoxic treatments were most affected by ATR inhibition and FANCA ko. In UM-SCC-1 cells only, 8 Gy X-rays promoted IFN-1 expression unaltered by abrogation of the DDR or concomitant increased TREX1 expression. At a higher dose of 20 Gy, this effect was observed only for concurrent Chk1- or ATR-inhibition. FANCA ko or cisplatin treatment was ineffective in this regard. Our observations open new perspectives for the enhancement of cGAS/STING/IFN-1-mediated antitumor immune response in HNSCC by hypofractionated or stereotactic radiotherapy concepts in multimodal settings with immuno-oncological strategies.

Identifiants

pubmed: 37834346
pii: ijms241914900
doi: 10.3390/ijms241914900
pmc: PMC10573837
pii:
doi:

Substances chimiques

Cisplatin Q20Q21Q62J
Nucleotidyltransferases EC 2.7.7.-
ATR protein, human EC 2.7.11.1
Ataxia Telangiectasia Mutated Proteins EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

DNA Repair (Amst). 2020 Dec;96:102992
pubmed: 33069004
Nat Commun. 2019 Jan 9;10(1):100
pubmed: 30626869
Nat Rev Cancer. 2018 May;18(5):313-322
pubmed: 29449659
Int J Mol Sci. 2021 Feb 03;22(4):
pubmed: 33546122
Nature. 2017 Aug 24;548(7668):466-470
pubmed: 28759889
Lancet Oncol. 2021 Apr;22(4):450-462
pubmed: 33794205
Oncotarget. 2017 Dec 11;8(69):114210-114225
pubmed: 29371980
Front Oncol. 2020 Jan 22;9:1522
pubmed: 32039012
Cancer Cell. 2021 Apr 12;39(4):494-508.e5
pubmed: 33545063
Front Oncol. 2019 Mar 19;9:156
pubmed: 30941308
J Clin Invest. 2020 Apr 1;130(4):1635-1652
pubmed: 31874109
J Surg Oncol. 2014 Oct;110(5):551-74
pubmed: 25053506
Cancer. 2017 Oct 15;123(20):3943-3954
pubmed: 28678401
Oncotarget. 2018 Apr 6;9(26):18198-18213
pubmed: 29719599
Haematologica. 2008 Apr;93(4):511-7
pubmed: 18322251
ORL J Otorhinolaryngol Relat Spec. 2007;69(4):218-25
pubmed: 17409780
Ann Oncol. 2023 Jan;34(1):101-110
pubmed: 36522816
EBioMedicine. 2016 Jun;8:184-194
pubmed: 27428429
Acta Otolaryngol. 1996 Mar;116(2):341-4
pubmed: 8725545
Mol Cancer Ther. 2020 Jun;19(6):1279-1288
pubmed: 32371584
EMBO J. 2013 Oct 16;32(20):2751-63
pubmed: 24065129
N Engl J Med. 2020 Jan 2;382(1):60-72
pubmed: 31893516
PLoS One. 2017 Nov 14;12(11):e0187532
pubmed: 29135982
Front Immunol. 2021 Jan 28;11:625833
pubmed: 33633744
Front Oncol. 2021 Feb 26;11:623964
pubmed: 33718186
Front Mol Biosci. 2023 Aug 01;10:1148389
pubmed: 37602328
Nat Protoc. 2014 Sep;9(9):2045-60
pubmed: 25079428
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Microbiol Immunol Infect. 2021 Aug;54(4):733-739
pubmed: 32768338
Nat Rev Dis Primers. 2020 Nov 26;6(1):92
pubmed: 33243986
Nat Rev Clin Oncol. 2023 Aug;20(8):543-557
pubmed: 37280366
Nature. 2017 Aug 24;548(7668):461-465
pubmed: 28738408
DNA Repair (Amst). 2023 Feb;122:103435
pubmed: 36549044
Nat Commun. 2017 Jun 09;8:15618
pubmed: 28598415
Front Oncol. 2020 Aug 07;10:1338
pubmed: 32850427
Front Oral Health. 2023 Jul 11;4:1180869
pubmed: 37496754
Expert Rev Mol Med. 2022 Feb 01;24:e8
pubmed: 35101155
Arch Otolaryngol Head Neck Surg. 2003 Jan;129(1):106-12
pubmed: 12525204
Int J Cancer. 2023 Jul 1;153(1):183-196
pubmed: 36912284
Nat Rev Genet. 2019 Nov;20(11):657-674
pubmed: 31358977
Mol Cell. 2023 Jan 19;83(2):266-280.e6
pubmed: 36638783
Ann Oncol. 2012 Sep;23 Suppl 10:x173-7
pubmed: 22987957
Oncogenesis. 2019 Jun 17;8(7):38
pubmed: 31209198
Cell Oncol (Dordr). 2022 Feb;45(1):1-18
pubmed: 35015241
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Front Cell Infect Microbiol. 2022 Feb 07;12:820273
pubmed: 35198459
Clin Cancer Res. 2019 Jun 1;25(11):3392-3403
pubmed: 30770349
Cancer Sci. 2019 Nov;110(11):3415-3423
pubmed: 31513320
EMBO J. 2020 Jul 15;39(14):e104036
pubmed: 32484965
Nat Commun. 2017 Nov 24;8(1):1751
pubmed: 29170499
J Clin Oncol. 2015 Oct 10;33(29):3305-13
pubmed: 26351341
Science. 2015 Oct 30;350(6260):568-71
pubmed: 26405230
Radiother Oncol. 2013 Sep;108(3):495-9
pubmed: 23932155
FEBS J. 2021 Aug;288(15):4507-4540
pubmed: 33529438
Oncotarget. 2017 Jun 16;8(58):97920-97927
pubmed: 29228662
Nature. 2022 Dec;612(7940):495-502
pubmed: 36450981
Annu Rev Cancer Biol. 2019 Mar;3:457-478
pubmed: 30882047
J Clin Oncol. 2017 May 10;35(14):1542-1549
pubmed: 28328302
Microb Pathog. 2019 Jul;132:162-165
pubmed: 31054871
Anticancer Res. 1993 Sep-Oct;13(5A):1405-13
pubmed: 8239512
J Natl Compr Canc Netw. 2017 Jun;15(6):761-770
pubmed: 28596256
Int J Oncol. 2011 Aug;39(2):505-14
pubmed: 21567085
Genes (Basel). 2021 Jun 17;12(6):
pubmed: 34204447
Clin Cancer Res. 2021 Oct 1;27(19):5168-5187
pubmed: 34045293
Cells. 2021 Apr 17;10(4):
pubmed: 33920544
Future Oncol. 2020 Jun;16(18):1235-1243
pubmed: 32490686

Auteurs

Sebastian Zahnreich (S)

Department of Radiation Oncology and Radiation Therapy, University Medical Centre of the Johannes Gutenberg, University Mainz, 55131 Mainz, Germany.

Soumia El Guerzyfy (S)

Department of Radiation Oncology and Radiation Therapy, University Medical Centre of the Johannes Gutenberg, University Mainz, 55131 Mainz, Germany.

Justus Kaufmann (J)

Department of Radiation Oncology and Radiation Therapy, University Medical Centre of the Johannes Gutenberg, University Mainz, 55131 Mainz, Germany.

Heinz Schmidberger (H)

Department of Radiation Oncology and Radiation Therapy, University Medical Centre of the Johannes Gutenberg, University Mainz, 55131 Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH